Cargando…
Licochalcone A: A Potential Multitarget Drug for Alzheimer’s Disease Treatment
Licochalcone A (Lico-A) is a flavonoid compound derived from the root of the Glycyrrhiza species, a plant commonly used in traditional Chinese medicine. While the Glycyrrhiza species has shown promise in treating various diseases such as cancer, obesity, and skin diseases due to its active compounds...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531537/ https://www.ncbi.nlm.nih.gov/pubmed/37762479 http://dx.doi.org/10.3390/ijms241814177 |
_version_ | 1785111742303436800 |
---|---|
author | Olloquequi, Jordi Ettcheto, Miren Cano, Amanda Fortuna, Ana Bicker, Joana Sánchez-Lopez, Elena Paz, Cristian Ureña, Jesús Verdaguer, Ester Auladell, Carme Camins, Antoni |
author_facet | Olloquequi, Jordi Ettcheto, Miren Cano, Amanda Fortuna, Ana Bicker, Joana Sánchez-Lopez, Elena Paz, Cristian Ureña, Jesús Verdaguer, Ester Auladell, Carme Camins, Antoni |
author_sort | Olloquequi, Jordi |
collection | PubMed |
description | Licochalcone A (Lico-A) is a flavonoid compound derived from the root of the Glycyrrhiza species, a plant commonly used in traditional Chinese medicine. While the Glycyrrhiza species has shown promise in treating various diseases such as cancer, obesity, and skin diseases due to its active compounds, the investigation of Licochalcone A’s effects on the central nervous system and its potential application in Alzheimer’s disease (AD) treatment have garnered significant interest. Studies have reported the neuroprotective effects of Lico-A, suggesting its potential as a multitarget compound. Lico-A acts as a PTP1B inhibitor, enhancing cognitive activity through the BDNF-TrkB pathway and exhibiting inhibitory effects on microglia activation, which enables mitigation of neuroinflammation. Moreover, Lico-A inhibits c-Jun N-terminal kinase 1, a key enzyme involved in tau phosphorylation, and modulates the brain insulin receptor, which plays a role in cognitive processes. Lico-A also acts as an acetylcholinesterase inhibitor, leading to increased levels of the neurotransmitter acetylcholine (Ach) in the brain. This mechanism enhances cognitive capacity in individuals with AD. Finally, Lico-A has shown the ability to reduce amyloid plaques, a hallmark of AD, and exhibits antioxidant properties by activating the nuclear factor erythroid 2-related factor 2 (Nrf2), a key regulator of antioxidant defense mechanisms. In the present review, we discuss the available findings analyzing the potential of Lico-A as a neuroprotective agent. Continued research on Lico-A holds promise for the development of novel treatments for cognitive disorders and neurodegenerative diseases, including AD. Further investigations into its multitarget action and elucidation of underlying mechanisms will contribute to our understanding of its therapeutic potential. |
format | Online Article Text |
id | pubmed-10531537 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105315372023-09-28 Licochalcone A: A Potential Multitarget Drug for Alzheimer’s Disease Treatment Olloquequi, Jordi Ettcheto, Miren Cano, Amanda Fortuna, Ana Bicker, Joana Sánchez-Lopez, Elena Paz, Cristian Ureña, Jesús Verdaguer, Ester Auladell, Carme Camins, Antoni Int J Mol Sci Review Licochalcone A (Lico-A) is a flavonoid compound derived from the root of the Glycyrrhiza species, a plant commonly used in traditional Chinese medicine. While the Glycyrrhiza species has shown promise in treating various diseases such as cancer, obesity, and skin diseases due to its active compounds, the investigation of Licochalcone A’s effects on the central nervous system and its potential application in Alzheimer’s disease (AD) treatment have garnered significant interest. Studies have reported the neuroprotective effects of Lico-A, suggesting its potential as a multitarget compound. Lico-A acts as a PTP1B inhibitor, enhancing cognitive activity through the BDNF-TrkB pathway and exhibiting inhibitory effects on microglia activation, which enables mitigation of neuroinflammation. Moreover, Lico-A inhibits c-Jun N-terminal kinase 1, a key enzyme involved in tau phosphorylation, and modulates the brain insulin receptor, which plays a role in cognitive processes. Lico-A also acts as an acetylcholinesterase inhibitor, leading to increased levels of the neurotransmitter acetylcholine (Ach) in the brain. This mechanism enhances cognitive capacity in individuals with AD. Finally, Lico-A has shown the ability to reduce amyloid plaques, a hallmark of AD, and exhibits antioxidant properties by activating the nuclear factor erythroid 2-related factor 2 (Nrf2), a key regulator of antioxidant defense mechanisms. In the present review, we discuss the available findings analyzing the potential of Lico-A as a neuroprotective agent. Continued research on Lico-A holds promise for the development of novel treatments for cognitive disorders and neurodegenerative diseases, including AD. Further investigations into its multitarget action and elucidation of underlying mechanisms will contribute to our understanding of its therapeutic potential. MDPI 2023-09-16 /pmc/articles/PMC10531537/ /pubmed/37762479 http://dx.doi.org/10.3390/ijms241814177 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Olloquequi, Jordi Ettcheto, Miren Cano, Amanda Fortuna, Ana Bicker, Joana Sánchez-Lopez, Elena Paz, Cristian Ureña, Jesús Verdaguer, Ester Auladell, Carme Camins, Antoni Licochalcone A: A Potential Multitarget Drug for Alzheimer’s Disease Treatment |
title | Licochalcone A: A Potential Multitarget Drug for Alzheimer’s Disease Treatment |
title_full | Licochalcone A: A Potential Multitarget Drug for Alzheimer’s Disease Treatment |
title_fullStr | Licochalcone A: A Potential Multitarget Drug for Alzheimer’s Disease Treatment |
title_full_unstemmed | Licochalcone A: A Potential Multitarget Drug for Alzheimer’s Disease Treatment |
title_short | Licochalcone A: A Potential Multitarget Drug for Alzheimer’s Disease Treatment |
title_sort | licochalcone a: a potential multitarget drug for alzheimer’s disease treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531537/ https://www.ncbi.nlm.nih.gov/pubmed/37762479 http://dx.doi.org/10.3390/ijms241814177 |
work_keys_str_mv | AT olloquequijordi licochalconeaapotentialmultitargetdrugforalzheimersdiseasetreatment AT ettchetomiren licochalconeaapotentialmultitargetdrugforalzheimersdiseasetreatment AT canoamanda licochalconeaapotentialmultitargetdrugforalzheimersdiseasetreatment AT fortunaana licochalconeaapotentialmultitargetdrugforalzheimersdiseasetreatment AT bickerjoana licochalconeaapotentialmultitargetdrugforalzheimersdiseasetreatment AT sanchezlopezelena licochalconeaapotentialmultitargetdrugforalzheimersdiseasetreatment AT pazcristian licochalconeaapotentialmultitargetdrugforalzheimersdiseasetreatment AT urenajesus licochalconeaapotentialmultitargetdrugforalzheimersdiseasetreatment AT verdaguerester licochalconeaapotentialmultitargetdrugforalzheimersdiseasetreatment AT auladellcarme licochalconeaapotentialmultitargetdrugforalzheimersdiseasetreatment AT caminsantoni licochalconeaapotentialmultitargetdrugforalzheimersdiseasetreatment |